Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia

European Urology

Volumn 37, Issue 3, 2000, Pages 306-313

  Van Kerrebroeck, P ^a   Jardin, A ^b   Laval, K U ^c   Van Cangh, P ^d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BICÊTRE HOSPITAL   (France)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

Benign prostatic hyperplasia; Placebo; Prolonged release formulation alfuzosin; Uroselective 1 blocker

Indexed keywords

ALFUZOSIN; PLACEBO;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; SCORING SYSTEM; SIDE EFFECT; UROFLOWMETRY; VASODILATATION; VERTIGO;

EID: 0033998198     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052361     Document Type: Article

References (30)